A systematic review and NMA of 48 RCTs (n=3,963 children and adults) compared the efficacy and safety of pharmacologic (including biologics and swallowed topical corticosteroids), dietary (food elimination diets), and mechanical interventions for eosinophilic esophagitis, searching databases to March 17, 2026.
High-frequency dupilumab produced the greatest symptom reduction vs. placebo (MD -11.08, 95% CI -15.14 to -7.03; high certainty) and quality-of-life gain (MD +6.57, 95% CI 3.42 to 9.71; moderate certainty); swallowed topical corticosteroids were also highly effective for both outcomes (symptom MD -6.86; QoL MD +7.20; moderate certainty). Four- and six-food elimination diets showed modest symptom benefit over 1-food elimination diet (low certainty), and most interventions did not increase harms versus placebo.
Certainty of evidence for food elimination diets was low; histologic improvement across interventions did not reliably predict patient-important outcomes; the network relied on indirect comparisons across heterogeneous trial populations.
Prioritize high-frequency dupilumab or swallowed topical corticosteroids as first-line pharmacotherapy for EoE, as both achieve meaningful symptom and quality-of-life gains with favorable safety profiles. Advise patients considering multi-food elimination diets that benefits are modest and come with significant dietary burden.
Explore related topics